Can I Take Glycine With Rapamycin (Sirolimus)?

What You Are Actually Asking (and Why It Matters for Women)

Most questions about rapamycin and supplements focus on obvious cytochrome P450 interactions. Glycine does not use that pathway. Still, combining glycine with sirolimus raises three specific concerns worth working through carefully, and two of them are particularly relevant to women's physiology.

Sirolimus (brand name Rapamune) is an mTOR inhibitor originally approved for kidney transplant rejection prevention. Off-label, it is used at low weekly doses (1 to 6 mg) for longevity purposes, a practice growing in popularity among women in their 40s and beyond who are managing metabolic and aging concerns. Glycine is an amino acid sold as a sleep aid, gut-health supplement, and collagen precursor, typically in doses of 3 to 10 g daily.

The combination is common in the longevity supplement space. Women deserve a clear answer about whether it is safe, and where the real uncertainties lie.

How Rapamycin Works (and Why mTOR Matters in Women)

Rapamycin inhibits mTORC1, the mechanistic target of rapamycin complex 1. MTORC1 acts as a cellular nutrient sensor: when it is active, cells grow and divide; when it is suppressed, autophagy increases and cellular "clean-up" accelerates. mTORC1 suppression extends lifespan in multiple model organisms, which is the rationale behind off-label longevity use.

mTOR and Women's Reproductive Biology

MTOR is not just a longevity target. It is deeply woven into ovarian biology. mTORC1 regulates primordial follicle activation, and excessive mTOR suppression in animal models depletes the ovarian reserve prematurely. This is directly relevant to women who are trying to conceive or who are in early perimenopause and concerned about remaining fertility. No large human trials have specifically examined rapamycin's effect on ovarian reserve in premenopausal women. That evidence gap is real, and your prescriber should know you are premenopausal if longevity dosing is being considered.

mTOR and Menopause

After menopause, the ovarian follicle concern is less pressing, but mTOR still regulates bone turnover, immune aging, and visceral fat metabolism. Post-menopausal women carry higher baseline insulin resistance, which makes the glucose-elevating side effect of sirolimus particularly worth monitoring in this group.

What Glycine Does (Mechanism)

Glycine is a conditionally essential amino acid that functions as an inhibitory neurotransmitter in the central nervous system and as a major building block of collagen (roughly one-third of collagen's amino acid content is glycine). Its main documented pharmacological actions are:

• Activation of glycine receptors (GlyR) in the spinal cord and brainstem, producing mild sedation and core body-temperature lowering at bedtime
• Modulation of NMDA glutamate receptors, contributing to its sleep-quality effects
• Acting as a co-substrate with proline and hydroxylysine in collagen triple-helix formation
• Modest insulin-sensitizing effects via GLP-1 potentiation and glucagon suppression in some human studies

None of these pathways involve CYP3A4, P-glycoprotein, or the other metabolic enzymes that govern most drug-supplement interactions with sirolimus.

Pharmacokinetic Interaction: Is There One?

The short answer is no, there is no known pharmacokinetic interaction between glycine and sirolimus.

Sirolimus is metabolized primarily by CYP3A4 and P-glycoprotein (P-gp). Significant interactions occur with CYP3A4 inhibitors (grapefruit, voriconazole, diltiazem) and inducers (rifampin, St. John's Wort). Glycine is not a substrate, inhibitor, or inducer of CYP3A4 or P-gp. It is absorbed via specific amino acid transporters in the small intestine and cleared renally. There is no plausible mechanism by which glycine would change sirolimus blood levels.

Sex Differences in Sirolimus Pharmacokinetics

Women metabolize sirolimus differently from men, and this is clinically meaningful. Population pharmacokinetic analyses of sirolimus show that women have a shorter apparent half-life (approximately 62 hours) compared with men (approximately 79 hours), and a higher oral clearance relative to body weight. In practical terms, women at a given sirolimus dose may have lower trough levels than men of similar weight. Some clinicians who prescribe off-label longevity sirolimus are not yet accounting for this sex difference when dosing. Ask your prescriber whether your trough level has been checked.

Pharmacodynamic Interactions: Where Caution Is Warranted

This is where the real clinical conversation needs to happen. Three pharmacodynamic overlaps between glycine and sirolimus are worth discussing with your provider.

1. Blood Glucose and Insulin Sensitivity

Sirolimus impairs insulin signaling, independently of weight, by interfering with downstream mTORC1 and mTORC2 signaling in pancreatic beta cells and peripheral tissues. In the DIRECT trial, sirolimus increased fasting glucose and HbA1c in kidney transplant recipients. Women with PCOS, pre-diabetes, or post-menopausal insulin resistance are at particular risk for sirolimus-induced hyperglycemia.

Glycine, by contrast, may improve insulin sensitivity. A randomized controlled trial in obese adults found that 15 g glycine daily for 3 months reduced markers of oxidative stress and improved insulin sensitivity. A smaller study in women with metabolic syndrome found modest reductions in fasting insulin with 15 g glycine daily.

The pharmacodynamic direction here is opposite: sirolimus tends to raise glucose, glycine tends to modestly lower it. For most women, this means glycine does not add glycemic danger on top of sirolimus. In fact, some clinicians who prescribe sirolimus for longevity view glycine's modest insulin-sensitizing effects as potentially complementary, though no clinical trial has tested this combination directly. If you are diabetic or on insulin or a sulfonylurea, adding glycine still warrants a conversation about hypoglycemia risk from the combination of the glucose-lowering drug plus glycine.

2. MTOR Pathway and Amino Acid Signaling

This is the interaction that makes longevity practitioners pause. MTORC1 senses amino acid availability as a signal to activate anabolic processes. Amino acids, including glycine, can activate mTORC1 through the Ragulator-Rag GTPase complex and specific amino acid sensors.

In vitro studies show that glycine alone is a relatively weak mTORC1 activator compared with leucine or arginine. At physiological concentrations achieved by oral glycine supplementation (3 to 10 g), the mTORC1 stimulation is modest. But at high doses (15 g or more), or when glycine is taken alongside protein-rich meals, there is a theoretical possibility of partially blunting the mTOR suppression you are trying to achieve with rapamycin.

A practical timing framework for women on longevity rapamycin: Because mTORC1 activation from amino acids is transient (peak within 1 to 2 hours of ingestion and largely resolved within 4 hours), separating your sirolimus dose from large protein or glycine doses by at least 4 to 6 hours may minimize any transient amino acid signaling that could counteract rapamycin's effect. This framework has not been tested in a clinical trial; it is derived from the pharmacodynamics of each agent and represents a reasonable, low-risk precaution.

3. Collagen Synthesis and Wound Healing

Sirolimus suppresses mTORC1-dependent protein synthesis, which slows wound healing and collagen production. This is a known clinical issue in transplant surgery: sirolimus is sometimes held perioperatively to reduce wound complications. A systematic review confirmed impaired wound healing as a class effect of mTOR inhibitors.

Glycine supplementation has been shown to support collagen synthesis by providing the rate-limiting amino acid substrate. A randomized trial found that 10 g glycine daily improved collagen stability in tendons in healthy older adults.

The question is whether glycine can offset sirolimus's wound-healing suppression. The mechanistic answer is: only partially. Glycine provides substrate for collagen production, but sirolimus suppresses the mTOR-dependent signaling that drives fibroblast proliferation and matrix deposition. Substrate availability does not rescue a signal that is pharmacologically blocked. Women recovering from surgery, dental procedures, or skin procedures should flag their sirolimus use regardless of glycine co-administration.

Specific Life-Stage Considerations

Reproductive Years (Ages 18 to 40)

If you are in your reproductive years and taking sirolimus off-label for longevity, you need to know that animal data show sirolimus is embryotoxic and fetotoxic. The FDA has not assigned a simple letter category since 2015, but the clinical guidance is clear: do not take sirolimus if you are pregnant or planning to become pregnant without a serious medical indication and specialist guidance.

Women of reproductive potential on sirolimus should use highly effective contraception (IUD, implant, or combined hormonal methods) throughout treatment and for 12 weeks after stopping. This requirement exists regardless of whether you also take glycine.

Glycine is generally regarded as safe in pregnancy as a dietary amino acid, though high-dose supplement use has not been studied in controlled trials in pregnant women.

Trying to Conceive (TTC)

If you are trying to conceive, sirolimus should be discontinued at least 12 weeks before attempting pregnancy. Glycine at dietary or moderate supplement doses (3 to 5 g daily) does not raise fertility concerns. Some small studies suggest glycine may support oocyte quality indirectly through its role in glutathione synthesis, but evidence in humans is preliminary.

Perimenopause (Ages 40 to 55, Approximate)

Women in perimenopause represent a significant portion of the off-label longevity sirolimus user base. Fluctuating estrogen during perimenopause already affects insulin sensitivity, sleep architecture, and collagen production. Glycine at 3 g at bedtime addresses the sleep concern specifically: a double-blind crossover trial published in Sleep and Biological Rhythms found that 3 g glycine at bedtime significantly improved subjective sleep quality and reduced daytime sleepiness in adults with self-reported poor sleep. This is a clinically meaningful benefit for perimenopausal women dealing with sirolimus-related sleep disruption or the sleep fragmentation of perimenopause itself.

Monitor fasting glucose every 3 months if you are combining sirolimus with any dose of glycine, particularly if you are also on progestogen-only contraception, which independently worsens insulin sensitivity.

Post-Menopause

Post-menopausal women on sirolimus face the highest glycemic risk, given baseline increases in visceral adiposity and insulin resistance after estrogen withdrawal. Glycine's modest insulin-sensitizing effect is unlikely to fully counterbalance sirolimus's glucose-raising tendency. A low-carbohydrate dietary pattern and regular resistance training remain the most evidence-supported strategies for managing sirolimus-induced metabolic changes in this group.

Bone health is also relevant. Sirolimus has complex effects on bone: it suppresses osteoclast activity (potentially protective) but also reduces osteoblast activity (potentially harmful). Glycine supports collagen cross-linking in bone matrix. Whether this translates to a clinically meaningful bone benefit in post-menopausal women on sirolimus is unknown. DEXA scanning at baseline and every 2 years is reasonable practice.

Pregnancy and Lactation Safety

Pregnancy: Sirolimus is contraindicated during pregnancy outside of highly specific transplant indications managed by a maternal-fetal medicine specialist. Pre-clinical data show fetal toxicity at sub-therapeutic maternal doses. Human data are limited to case reports and small transplant registries, which show increased rates of preterm birth and low birth weight. If you discover you are pregnant while taking sirolimus, contact your prescriber immediately.

Glycine at dietary amounts is present in all protein-containing foods and is not a pregnancy concern. High-dose glycine supplements (above 10 g daily) have not been studied in controlled human pregnancy trials. Keeping glycine at 3 to 5 g daily during pregnancy, if your provider approves continuation, is the conservative approach.

Lactation: Sirolimus transfers into human breast milk. Breastfeeding is not recommended during sirolimus therapy due to the potential for immunosuppression in the nursing infant. Glycine transfers into breast milk as a dietary amino acid and at supplement doses is not considered a breastfeeding concern.

Contraception: Women of reproductive age on sirolimus must use effective non-barrier contraception throughout treatment and for 12 weeks after the last dose. Combined hormonal contraceptives do not have a clinically significant pharmacokinetic interaction with sirolimus, but you should confirm your contraceptive choice with your prescriber.

Who This Combination Is Likely Safe For

Women who are good candidates for glycine alongside sirolimus:

• Post-menopausal women using sirolimus for longevity who want sleep support or collagen benefits, with regular glucose monitoring in place
• Perimenopausal women with poor sleep quality who are already on longevity-dose sirolimus, using 3 g glycine at bedtime separated from the sirolimus dose
• Kidney transplant recipients not on concurrent immunosuppressants that interact with glycine's glycemic effects, with nephrologist awareness

Who Should Be More Cautious

Women for whom adding glycine warrants a specific conversation before proceeding:

• Women on insulin or sulfonylureas alongside sirolimus (additive glucose-lowering possible)
• Women with PCOS who are already on metformin plus sirolimus (triple glucose-lowering mechanism)
• Women taking high-dose glycine (15 g or more daily) who use sirolimus for longevity and want to preserve maximum mTOR suppression
• Women who are pregnant, planning pregnancy within 12 weeks, or breastfeeding (due to sirolimus, not glycine)
• Women recovering from recent surgery or with active wounds

Monitoring Plan If You Take Both

Your provider should track:

| Parameter | Frequency | Notes | |---|---|---| | Fasting glucose and HbA1c | Every 3 months | Sirolimus raises glucose; glycine may partially offset | | Sirolimus trough level | Every 3 months or after dose change | Women have higher clearance; trough <5 ng/mL common in longevity dosing | | Lipid panel | Every 3 months | Sirolimus raises triglycerides; glycine neutral | | CBC with differential | Every 3 months | Immunosuppression monitoring | | Renal function (BMP) | Every 6 months | Standard sirolimus monitoring | | DEXA (post-menopausal) | Every 2 years | Bone effects uncertain |

Evidence Gaps and What Is Extrapolated

Women have been under-represented in sirolimus pharmacokinetic trials, most of which were conducted in male kidney transplant recipients. The sex-specific half-life data cited above comes from a population PK model, not a dedicated women's trial. Off-label longevity dosing in women has no published randomized controlled trial data. The PEARL trial examined rapamycin in older adults for aging biomarkers but enrolled a mixed-sex cohort and did not stratify by sex for primary outcomes.

Glycine-mTOR interaction data is almost entirely from cell-culture and rodent studies. The clinical relevance of glycine-mediated mTOR stimulation at supplement doses in humans has not been tested in a controlled trial, in either men or women.

Be appropriately skeptical of confident claims in either direction from longevity content that does not acknowledge these gaps.